Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
N/A
1(25.0%)
4Total
Phase 4(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07173712Phase 4Not Yet Recruiting

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

Role: lead

NCT07198932Not Yet Recruiting

Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

Role: lead

NCT06007014Not ApplicableUnknown

Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes

Role: lead

NCT03958591Phase 4Unknown

Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification

Role: lead

NCT03320031Phase 4Unknown

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

Role: lead

All 5 trials loaded